Safilo Group stock
SFL.MIMILSafilo Group S.p.A., HealthcareISIN IT0004604762
61Score 61 out of 100, Neutral
Price and trend
79 / 100
Price history
+26% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 31% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 82).
The price is at its 52-week high. Largest decline in 20 years: 99% (July 2007 to October 2020).
Chart figures for advanced users
- SMA 50$2.09
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$1.99
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)82
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$1.67
- The lowest closing price of the last twelve months.
- Resistance$2.60
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Safilo Group S.p.A. belongs to the Medical (Instruments & Supplies) industry (Italy) and, with a market value of $1.01B, is number 40 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.09B (down 1% year on year) and earnings of $54.38M (up 120.1%).
- For fiscal 2026, analysts expect on average revenue of $1.09B (down 0.3%) and adjusted earnings per share of $0.14.
Show more
- MEQIRI Score 61 out of 100 (Neutral): rank 260 of 702 in Healthcare, median 53.
- The P/E is 19.4 (Medical (Instruments & Supplies) median 34.6, own median of recent years 16.7).
- Our model puts fair value at $3.42, with the price 24% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings turn into cashFree cash flow 230% of earnings over the last 12 months.Fundamentals 52
Weaknesses
- DilutionShare count up 37% since 2020.Capital allocation 40
Its standout strengths are momentum and technical analysis, while growth and capital allocation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
What lowers it
- price near its 52-week high
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $2.44 and expensive above $5.69 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $2.19 (cash-flow model) and $4.64 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 9.1%. At 10.1% the fair value would be $3.27, at 8.1% it would be $3.63.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (34.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue fell 4.1% on the twelve months before. Revenue has stayed largely stable since 2006.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 58%, operating 7%, net 5%.
Debt & balance sheet
latest quarterLow debt, and interest is adequately covered.
Earnings
- Next earnings
- 16 Mar 2027in 123 days
- Last reported
- 4 Aug 2026EPS reported $0.12
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.140.0%
- Revenue
- $1.09B0.0%
- Earnings per share
- $0.150.0%
- Revenue
- $1.14B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +5.5%No new guidance; after the weak second quarter (Asia Pacific down 17.7%) a recovery is expected in the second half, mainly in North America.
“In Asia Pacific, where second quarter sales were down 17.7% at constant exchange rates, performance was held back by a combination of factors, a particularly demanding comparison base as the region was up 11.5% in the second quarter of 2025, soft market condition in China and the rescheduling of the Xiamen optical …”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 3 Aug 2026 (fiscal Q2 2026), read by AI.
What happened at Safilo Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 61
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- LeMaitre VascularLMAT $1.78B70
- Kestra Medical TechnologiesKMTS $1.7B43
- STAAR SurgicalSTAA $1.34B44
- GerresheimerGXI.DE $1.21B48
- Dynavox GroupDYVOX.ST $784.35M67
- AngioDynamicsANGO $504.23M39
- EmbectaEMBC $364.32M63
- COLTENE HoldingCLTN.SW $347.49M61
ETFs that hold Safilo Group
Held by 9 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI EMU Small Cap UCITS ETFSXRJ | 0.07% | 0.58% | €838.19M |
| Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF DISTLGWU | 0.04% | 0.40% | €580.62M |
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.03% | 0.39% | €1.49B |
Show 5 more
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.03% | 0.30% | €813.64M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.03% | 0.30% | €3.45B |
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.01% | 0.23% | €321.86M |
| UBS MSCI EMU Select Factor Mix UCITS ETF EUR accUIQN | 0.01% | 0.34% | €16.96M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.84B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Jul 2025)
- Valuation signal Fairly valued since 13 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.